Granzer Regulatory Consulting & Services was founded at the beginning of 2002 by Dr. Ulrich Granzer and offers a wide range of services in the field of regulatory affairs.
Their team comprises a staff of experienced consultants who have backgrounds in large and small pharma as well as biotech. They have know-how and proficiency in the various disciplines required for drug development.
Since more than 15 years the team of dedicated senior executives with decades of professional experience from the pharmaceutical and biotechnology industry provides transaction advisory services on a global basis (sell and buy side) to international biotech, pharmaceutical, medtech and investment companies. Their track-record comprises all customary agreement types in many indication areas and throughout all stages in product development with a transaction value exceeding to date a total of US$ 4 bn.
Staatz BD&S further advises clients from the international industry on market access and pricing & reimbursement strategies and operations for European markets. They have successfully developed and implemented Market Access Strategies to consider in product development including the development and testing of value messages. They prepare HTA dossiers, provide pricing and reimbursement assessment and price negotiation support.